RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder (REFRESH)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01490086 |
Recruitment Status :
Completed
First Posted : December 12, 2011
Results First Posted : January 26, 2015
Last Update Posted : January 26, 2015
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Acute Schizophrenia Schizoaffective Disorder | Drug: RP5063 Drug: placebo Drug: aripiprazole | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 234 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | REFRESH : Randomized Double-blind, Placebo-controlled, Multicenter Trial to Assess the Safety and Efficacy of RP5063 in Subjects With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder |
Study Start Date : | December 2011 |
Actual Primary Completion Date : | March 2013 |
Actual Study Completion Date : | March 2013 |

Arm | Intervention/treatment |
---|---|
Experimental: 15mg RP5063 daily |
Drug: RP5063
daily |
Experimental: 30mg RP5063 daily |
Drug: RP5063
daily |
Experimental: 50mg RP5063 daily |
Drug: RP5063
daily |
Placebo Comparator: Placebo |
Drug: placebo
daily |
Active Comparator: aripiprazole
aripiprazole 15 mg daily
|
Drug: aripiprazole
daily |
- Measurement of Schizophrenia Symptoms: Positive and Negative Syndrome Scale (PANSS) Total Score [ Time Frame: Baseline to Day 28 ]PANSS total score comprises Positive (Delusions, Conceptual disorganization, Hallucinatory behavior, Excitement, Grandiosity, Suspiciousness/persecution, Hostility), Negative (Blunted affect, Emotional withdrawal, Poor rapport, Passive/apathetic social withdrawal, Difficulty in abstract thinking, Lack of spontaneity and flow of conversation, Stereotyped thinking), and General Psychopathology (Somatic concern, Anxiety, Guilt feelings, Tension, Mannerisms and posturing, Depression, Motor retardation, Uncooperativeness, Unusual thought content, Disorientation, Poor attention, Lack of judgment and insight, Disturbance of volition, Poor impulse control, Preoccupation, Active social avoidance) Scales. Scores are obtained by adding the ratings of each item in each scale. Range is 7-49 for Positive and Negative scores; 16-112 for General Psychopathology score; and 30-210 for Total score. Higher score reflects worse outcome; larger reduction from baseline reflects better outcome.
- Demonstrates Antipsychotic Efficacy as Assessed by Change From Baseline on the Clinical Global Impression Scale - Severity (CGI-S) [ Time Frame: Baseline to Day 28 ]Clinical Global Impression, Severity (CGI-S) is a single-item (7-point) scale that evaluates the overall severity of the subject's mental illness. Scores range from 1 (not ill at all) to 7 (among the most extremely ill). A reduction in score indicates an improvement in the subject's condition.
- Demonstrates Antipsychotic Efficacy as Assessed by Change From Baseline on the PANSS Positive Subscale [ Time Frame: Baseline to Day 28 ]The Positive Scale includes 7 Items (Delusions, Conceptual disorganization, Hallucinations, Hyperactivity, Grandiosity, Suspiciousness/persecution, Hostility) and is calculated by adding the subscale item scores to obtain results ranging from 7 to 49. A higher score reflects worse outcome and a larger reduction in the score from baseline reflects better treatment efficacy.
- Demonstrates Antipsychotic Efficacy as Assessed by Change From Baseline on the PANSS Negative Subscale [ Time Frame: Baseline to Day 28 ]The Negative Scale includes 7 items (Blunted affect, Emotional withdrawal, Poor rapport, Passive/apathetic social withdrawal, Difficulty in abstract thinking, Lack of spontaneity and flow of conversation, Stereotyped thinking) and is calculated by adding the negative subscale item scores to obtain results ranging from 7 to 49. Minimum score is 7, maximum score is 49. A higher score reflects worse outcome and a larger reduction in the score from baseline reflects better treatment efficacy.
- Demonstrates Antipsychotic Efficacy as Assessed by Change From Baseline on the PANSS General Psychopathology Subscale [ Time Frame: Baseline to Day 28 ]The General Psychopathology Scale consists of 16 items (Somatic concern, Anxiety, Guilt feelings, Tension, Mannerisms and posturing, Depression, Motor retardation, Uncooperativeness, Unusual thought content, Disorientation, Poor attention, Lack of judgment and insight, Disturbance of volition, Poor impulse control, Preoccupation, Active social avoidance). The General Psychopathology score is obtained by adding the ratings of each item in the scale, with results ranging from 16 to 112. A higher score reflects worse outcome and a larger reduction in the score from baseline reflects better treatment efficacy.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients providing informed consent prior to any study specific procedures
- Patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for schizophrenia (paranoid type, disorganized type, catatonic type or undifferentiated type), or schizoaffective disorder
- Patients with normal physical examination, laboratory, vital signs,and electrocardiogram (ECG)
Exclusion Criteria:
- Patients with other primary psychiatric disorders as delirium, or bipolar I or II disorder

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01490086
United States, Pennsylvania | |
Reviva site | |
Philadelphia, Pennsylvania, United States, 19039 | |
India | |
Reviva site | |
Bangalore, India | |
Reviva site | |
Chennai, India | |
Reviva site | |
Guntur, India | |
Reviva site | |
Jaipur, India | |
Reviva site | |
Kanpur, India | |
Reviva site | |
Lucknow, India | |
Reviva site | |
Mangalore, India | |
Malaysia | |
Reviva site | |
Bahru, Malaysia | |
Reviva site | |
Johor, Malaysia | |
Reviva site | |
KLumpur, Malaysia | |
Reviva Site | |
Ridzuan, Malaysia | |
Moldova, Republic of | |
Reviva site | |
Kisinau, Moldova, Republic of | |
Philippines | |
Reviva site | |
Mandaluyon, Philippines | |
Reviva site | |
Mandurriao, Philippines | |
Reviva site | |
Subangdaku, Philippines |
Study Director: | M Cantillon | Fundacion REVIVA, Red de VIH del Valle del Cauca |
Responsible Party: | Reviva Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT01490086 |
Other Study ID Numbers: |
RVP-20-001 |
First Posted: | December 12, 2011 Key Record Dates |
Results First Posted: | January 26, 2015 |
Last Update Posted: | January 26, 2015 |
Last Verified: | January 2015 |
Schizophrenia Psychotic Disorders Schizophrenia Spectrum and Other Psychotic Disorders Mental Disorders Aripiprazole RP5063 Antidepressive Agents Psychotropic Drugs Antipsychotic Agents Tranquilizing Agents Central Nervous System Depressants Physiological Effects of Drugs |
Dopamine Agonists Dopamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Serotonin 5-HT1 Receptor Agonists Serotonin Receptor Agonists Serotonin Agents Serotonin 5-HT2 Receptor Antagonists Serotonin Antagonists Dopamine D2 Receptor Antagonists Dopamine Antagonists |